{"id":20857,"date":"2023-08-14T14:15:51","date_gmt":"2023-08-14T06:15:51","guid":{"rendered":"https:\/\/tbenews.com\/tbe\/?p=20857"},"modified":"2023-08-14T14:17:49","modified_gmt":"2023-08-14T06:17:49","slug":"snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus","status":"publish","type":"post","link":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/","title":{"rendered":"Snapshot week 33\/2023 <br>Testing nucleoside\/nucleotide analogs against TBE virus and West Nile virus"},"content":{"rendered":"<span class=\"cb-itemprop\" itemprop=\"reviewBody\">\n<p class=\"wp-block-paragraph\">Binderup et al.<br>Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines<br><em>Virology<\/em>. 2023;585:179-185. doi:10.1016\/j.virol.2023.06.002<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">There are no specific antiviral drugs available for TBE virus infections (see e.g., <a href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-2-2023-the-search-for-drugs-to-treat-tbe\/\">Snapshot week 2\/2023<\/a>). Various nucleoside analogs have been tested, among which are galidesivir and ribavirin.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Recently, ribavirin, a synthetic guanosine nucleoside analog which has some anticancer and antiviral properties and is known as a chemotherapeutic agent with activities against a wide range of RNA and DNA viruses, has been tested in cell lines as drug against TBE (see <a href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-32-2023-assessing-ribavirin-as-an-anti-tbe-virus-drug\/\">Snapshot week 32\/2023<\/a>). Now, a panel of nucleoside\/nucleotide analogs (nucs) have been tested in various human cell lines for activity against TBE virus and yellow fever virus.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">After an initial screening with 14 nucs, eight drugs were found active against TBE virus and yellow fever virus: remdesivir, GS-6620, sofosbuvir, uprifosbuvir, valopicitabine, galidesivir, ribavirin and molnupiravir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It was noticed that antiviral activity was cell-type dependent, most likely due to differences in metabolic activation between cell lines. Discrepancies between EC<sub>50<\/sub> values obtained here and previously reported were found, which emphasizes the difficulties of comparing drug activity due to differences in experimental systems and methodologies, e.g., ribavirin exhibited only moderate antiviral activity (which contrasts with <a href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-32-2023-assessing-ribavirin-as-an-anti-tbe-virus-drug\/\">Snapshot week 32\/2023<\/a>).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Remdesivir, sofosbuvir and uprifosbuvir were highly active against both viruses in Huh7.5 cells (uprifosbuvir already underwent clinical phase 3 studies for treatment of HCV). The highly potent remdesivir has however been associated with liver injury in a few COVID-19 patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The authors concluded that the best drug candidates against TBE virus and yellow fever virus may be remdesivir, sofosbuvir and uprifosbuvir. These compounds, originally found to inhibit HCV, and sofosbuvir and remdesivir currently used to treat chronic hepatitis C and COVID-19, respectively, could easily be repurposed for their use against TBE virus or yellow virus infection and merit further investigations in clinical studies.<\/p>\n<\/span>","protected":false},"excerpt":{"rendered":"<p>Binderup et al.Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell linesVirology. 2023;585:179-185. doi:10.1016\/j.virol.2023.06.002 There are no specific antiviral drugs available for TBE virus infections (see e.g., Snapshot week 2\/2023). Various nucleoside analogs have been tested, among which are galidesivir and ribavirin. Recently, ribavirin, a synthetic guanosine nucleoside analog which has some anticancer and antiviral properties and is known as a chemotherapeutic agent with activities against a wide range of RNA and DNA viruses, has been tested in cell lines as drug against TBE (see Snapshot week 32\/2023). Now, a panel of nucleoside\/nucleotide analogs (nucs) have been tested in various human cell lines for activity against TBE virus and yellow fever virus. After an initial screening with 14 nucs, eight drugs were found active against TBE virus and yellow fever virus: remdesivir, GS-6620, sofosbuvir, uprifosbuvir, valopicitabine, galidesivir, ribavirin and molnupiravir. It was noticed that antiviral activity was cell-type dependent, most likely due to differences in metabolic activation between cell lines. Discrepancies between EC50 values obtained here and previously reported were found, which emphasizes the difficulties of comparing drug activity due to differences in experimental systems and methodologies, e.g., ribavirin exhibited only moderate antiviral activity (which contrasts with Snapshot week 32\/2023). Remdesivir, sofosbuvir and uprifosbuvir were highly active against both viruses in Huh7.5 cells (uprifosbuvir already underwent clinical phase 3 studies for treatment of HCV). The highly potent remdesivir has however been associated with liver injury in a few COVID-19 patients. The authors concluded that the best drug candidates against TBE virus and yellow fever virus may be remdesivir, sofosbuvir and uprifosbuvir. These compounds, originally found to inhibit HCV, and sofosbuvir and remdesivir currently used to treat chronic hepatitis C and COVID-19, respectively, could easily be repurposed for their use against TBE virus or yellow virus infection and merit further investigations in clinical studies.<\/p>\n","protected":false},"author":1354,"featured_media":12864,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[18],"tags":[965,260,1035,1033,1034,1036],"coauthors":[581],"class_list":["post-20857","post","type-post","status-publish","format-standard","has-post-thumbnail","category-snapshot","tag-antivirals","tag-flavivirus","tag-nucleoside-nucleotide-analogs","tag-remdesivir","tag-sofosbuvir","tag-uprifosbuvir"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Snapshot week 33\/2023 Testing nucleoside\/nucleotide analogs against TBE virus and West Nile virus - TBE Book<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snapshot week 33\/2023 Testing nucleoside\/nucleotide analogs against TBE virus and West Nile virus - TBE Book\" \/>\n<meta property=\"og:description\" content=\"Binderup et al.Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell linesVirology. 2023;585:179-185. doi:10.1016\/j.virol.2023.06.002 There are no specific antiviral drugs available for TBE virus infections (see e.g., Snapshot week 2\/2023). Various nucleoside analogs have been tested, among which are galidesivir and ribavirin. Recently, ribavirin, a synthetic guanosine nucleoside analog which has some anticancer and antiviral properties and is known as a chemotherapeutic agent with activities against a wide range of RNA and DNA viruses, has been tested in cell lines as drug against TBE (see Snapshot week 32\/2023). Now, a panel of nucleoside\/nucleotide analogs (nucs) have been tested in various human cell lines for activity against TBE virus and yellow fever virus. After an initial screening with 14 nucs, eight drugs were found active against TBE virus and yellow fever virus: remdesivir, GS-6620, sofosbuvir, uprifosbuvir, valopicitabine, galidesivir, ribavirin and molnupiravir. It was noticed that antiviral activity was cell-type dependent, most likely due to differences in metabolic activation between cell lines. Discrepancies between EC50 values obtained here and previously reported were found, which emphasizes the difficulties of comparing drug activity due to differences in experimental systems and methodologies, e.g., ribavirin exhibited only moderate antiviral activity (which contrasts with Snapshot week 32\/2023). Remdesivir, sofosbuvir and uprifosbuvir were highly active against both viruses in Huh7.5 cells (uprifosbuvir already underwent clinical phase 3 studies for treatment of HCV). The highly potent remdesivir has however been associated with liver injury in a few COVID-19 patients. The authors concluded that the best drug candidates against TBE virus and yellow fever virus may be remdesivir, sofosbuvir and uprifosbuvir. These compounds, originally found to inhibit HCV, and sofosbuvir and remdesivir currently used to treat chronic hepatitis C and COVID-19, respectively, could easily be repurposed for their use against TBE virus or yellow virus infection and merit further investigations in clinical studies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/\" \/>\n<meta property=\"og:site_name\" content=\"TBE Book\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-14T06:15:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-14T06:17:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Shaqeez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shaqeez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\\\/\"},\"author\":{\"name\":\"Shaqeez\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2bc2ab1f56f93257537a0ce8de903224\"},\"headline\":\"Snapshot week 33\\\/2023 Testing nucleoside\\\/nucleotide analogs against TBE virus and West Nile virus\",\"datePublished\":\"2023-08-14T06:15:51+00:00\",\"dateModified\":\"2023-08-14T06:17:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\\\/\"},\"wordCount\":324,\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"keywords\":[\"antivirals\",\"flavivirus\",\"nucleoside\\\/nucleotide analogs\",\"remdesivir\",\"sofosbuvir\",\"uprifosbuvir\"],\"articleSection\":[\"Snapshot\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\\\/\",\"name\":\"Snapshot week 33\\\/2023 Testing nucleoside\\\/nucleotide analogs against TBE virus and West Nile virus - TBE Book\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"datePublished\":\"2023-08-14T06:15:51+00:00\",\"dateModified\":\"2023-08-14T06:17:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"width\":1180,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Snapshot week 33\\\/2023 Testing nucleoside\\\/nucleotide analogs against TBE virus and West Nile virus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"name\":\"The TBE Book\",\"description\":\"Tick-borne Encephalitis (TBE)\",\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\",\"name\":\"Global Health Press\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"width\":1000,\"height\":715,\"caption\":\"Global Health Press\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2bc2ab1f56f93257537a0ce8de903224\",\"name\":\"Shaqeez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g2ce4daa834e38f5ff18a9faa82d1596d\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g\",\"caption\":\"Shaqeez\"},\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/author\\\/shaqeez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Snapshot week 33\/2023 Testing nucleoside\/nucleotide analogs against TBE virus and West Nile virus - TBE Book","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/","og_locale":"en_US","og_type":"article","og_title":"Snapshot week 33\/2023 Testing nucleoside\/nucleotide analogs against TBE virus and West Nile virus - TBE Book","og_description":"Binderup et al.Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell linesVirology. 2023;585:179-185. doi:10.1016\/j.virol.2023.06.002 There are no specific antiviral drugs available for TBE virus infections (see e.g., Snapshot week 2\/2023). Various nucleoside analogs have been tested, among which are galidesivir and ribavirin. Recently, ribavirin, a synthetic guanosine nucleoside analog which has some anticancer and antiviral properties and is known as a chemotherapeutic agent with activities against a wide range of RNA and DNA viruses, has been tested in cell lines as drug against TBE (see Snapshot week 32\/2023). Now, a panel of nucleoside\/nucleotide analogs (nucs) have been tested in various human cell lines for activity against TBE virus and yellow fever virus. After an initial screening with 14 nucs, eight drugs were found active against TBE virus and yellow fever virus: remdesivir, GS-6620, sofosbuvir, uprifosbuvir, valopicitabine, galidesivir, ribavirin and molnupiravir. It was noticed that antiviral activity was cell-type dependent, most likely due to differences in metabolic activation between cell lines. Discrepancies between EC50 values obtained here and previously reported were found, which emphasizes the difficulties of comparing drug activity due to differences in experimental systems and methodologies, e.g., ribavirin exhibited only moderate antiviral activity (which contrasts with Snapshot week 32\/2023). Remdesivir, sofosbuvir and uprifosbuvir were highly active against both viruses in Huh7.5 cells (uprifosbuvir already underwent clinical phase 3 studies for treatment of HCV). The highly potent remdesivir has however been associated with liver injury in a few COVID-19 patients. The authors concluded that the best drug candidates against TBE virus and yellow fever virus may be remdesivir, sofosbuvir and uprifosbuvir. These compounds, originally found to inhibit HCV, and sofosbuvir and remdesivir currently used to treat chronic hepatitis C and COVID-19, respectively, could easily be repurposed for their use against TBE virus or yellow virus infection and merit further investigations in clinical studies.","og_url":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/","og_site_name":"TBE Book","article_published_time":"2023-08-14T06:15:51+00:00","article_modified_time":"2023-08-14T06:17:49+00:00","og_image":[{"width":1180,"height":250,"url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","type":"image\/jpeg"}],"author":"Shaqeez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Shaqeez","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/#article","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/"},"author":{"name":"Shaqeez","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2bc2ab1f56f93257537a0ce8de903224"},"headline":"Snapshot week 33\/2023 Testing nucleoside\/nucleotide analogs against TBE virus and West Nile virus","datePublished":"2023-08-14T06:15:51+00:00","dateModified":"2023-08-14T06:17:49+00:00","mainEntityOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/"},"wordCount":324,"publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","keywords":["antivirals","flavivirus","nucleoside\/nucleotide analogs","remdesivir","sofosbuvir","uprifosbuvir"],"articleSection":["Snapshot"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/","url":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/","name":"Snapshot week 33\/2023 Testing nucleoside\/nucleotide analogs against TBE virus and West Nile virus - TBE Book","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/#primaryimage"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","datePublished":"2023-08-14T06:15:51+00:00","dateModified":"2023-08-14T06:17:49+00:00","breadcrumb":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/#primaryimage","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","width":1180,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-33-2023-testing-nucleoside-nucleotide-analogs-against-tbe-virus-and-west-nile-virus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tbenews.com\/tbe\/"},{"@type":"ListItem","position":2,"name":"Snapshot week 33\/2023 Testing nucleoside\/nucleotide analogs against TBE virus and West Nile virus"}]},{"@type":"WebSite","@id":"https:\/\/tbenews.com\/tbe\/#website","url":"https:\/\/tbenews.com\/tbe\/","name":"The TBE Book","description":"Tick-borne Encephalitis (TBE)","publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tbenews.com\/tbe\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tbenews.com\/tbe\/#organization","name":"Global Health Press","url":"https:\/\/tbenews.com\/tbe\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","width":1000,"height":715,"caption":"Global Health Press"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2bc2ab1f56f93257537a0ce8de903224","name":"Shaqeez","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g2ce4daa834e38f5ff18a9faa82d1596d","url":"https:\/\/secure.gravatar.com\/avatar\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g","caption":"Shaqeez"},"url":"https:\/\/tbenews.com\/tbe\/author\/shaqeez\/"}]}},"_links":{"self":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/20857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/users\/1354"}],"replies":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/comments?post=20857"}],"version-history":[{"count":3,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/20857\/revisions"}],"predecessor-version":[{"id":20860,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/20857\/revisions\/20860"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media\/12864"}],"wp:attachment":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media?parent=20857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/categories?post=20857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/tags?post=20857"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/coauthors?post=20857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}